Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

Fig. 3

Expression of pro-inflammatory mediators in TCM from resected CRC tissue. The MSD V-plex Proinflammatory panel 1 was used to determine the expression level of 10 proinflammatory markers in tumor conditioned media generated from resected patient CRC tissue. a Treatment with FOLFOX and 1,4-dihydroxy quininib in combination with FOLFOX significantly increased IFN-γ expression (p < 0.01, FC = 1.6, and p < 0.05, FC = 1.5 respectively). b Treatment with 1,4-dihydroxy quininib significantly decreased the expression level of IL-6 (p < 0.05, FC = 2.3). c The expression level of IL-10 significantly decreased following treatment with 1,4-dihydroxy quininib (p < 0.01, FC = 5.1), 1,4-dihydroxy quininib in combination with Bevacizumab (p < 0.05, FC = 3.9), and 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.05, FC = 1.3) compared to control. d The expression level of IL-13 significantly decreased following treatment with 1,4-dihydroxy quininib (p < 0.05, FC = 1.5) and significantly increased following treatment with FOLFOX (p < 0.01, FC = 1.8) compared to control. Statistical analysis was performed using a paired non-parametric Wilcoxon signed rank test to determine significance between groups. (*p < 0.05, **p < 0.01). 1,4-dihydrox. Quin. = 1,4-dihydroxy quininib, Bev = Bevacizumab, FC = Fold Change. Error bars represent mean SEM. Non-significant results are found in Supplementary Figure 2

Back to article page